Gland Pharma has named Deepak Sapra, a senior leader from Dr. Reddy's Laboratories, as its next Chief Executive Officer. Set to join on November 16, 2026, Sapra brings over 27 years of experience to the role as the company aims to build on its recent growth.
Gland Pharma has officially named Deepak Sapra as its incoming Chief Executive Officer. The appointment follows board approval and a recommendation from the Nomination and Remuneration Committee. Mr. Sapra is scheduled to assume the leadership position on November 16, 2026, pending his formal acceptance of the offer.
Leadership Change During Growth Phase
This leadership transition occurs as Gland Pharma navigates a period of active growth. In its recent first-quarter results for the financial year 2027, the company reported a strong performance, with revenue growing 19.6% compared to the same period last year. Profitability also remained steady, with EBITDA margins reaching 27.2%. Investors are watching how the new management will sustain this momentum, particularly in the competitive global injectables and Contract Development and Manufacturing Organization (CDMO) markets.
Industry Background
Mr. Sapra brings over 27 years of executive experience to the company, with more than two decades specifically in the pharmaceutical industry. He currently serves as the CEO of API and Services at Dr. Reddy's Laboratories and is a board member at Aurigene Pharma Services. His career includes extensive work in business development, mergers and acquisitions, and global portfolio strategy. This background is relevant to Gland Pharma’s business model, which relies on complex manufacturing partnerships and access to international markets.
Operational Focus Areas
The new CEO will take charge at a time when the company is managing the integration of its acquired assets, such as the contract manufacturing operations at Cenexi. A key point for shareholders will be how the company balances its capital spending on new projects with the need to maintain stable profit margins in a fluctuating global sector. The market will track the transition process and any future strategic updates provided by the company as Mr. Sapra prepares to take the helm.